ReviewGut microbes2017
Intestinal IgA as a modulator of the gut microbiota.
Review in Gut microbes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 65 citations in OpenAlex.
- Immunomodulatory Role of Milk on Gut Microbiota: Implications for Enhancing Oral Vaccine Efficacy.Probiotics and antimicrobial proteins · 2026Review
- Purified diet reduces intestinal IgA and alters the microbiota accordingly.The British journal of nutrition · 2026Article
- Gut microbiota and uveitis: exploring novel mechanisms of inflammatory ocular diseases via the gut-eye axis.Frontiers in microbiology · 2026Review
- A newborn derived monoclonal IgM antibody selectively modulates microbial metabolism in the gut.Nature communications · 2025Article
- Prevalence of Anti-Pathogens (Basel, Switzerland) · 2025Article
- Gut Feelings: How Microbes, Diet, and Host Immunity Shape Disease.Biomedicines · 2025Review
- From Dysbiosis to Disease: The Microbiome's Influence on Uveitis Pathogenesis.Microorganisms · 2025Review
- Metabolic rewiring controlled by HIF-1α tunes IgA-producing B-cell differentiation and intestinal inflammation.Cellular & molecular immunology · 2025Article
- Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers.Seminars in immunopathology · 2024Review
- Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.Journal of gastroenterology · 2024Article
- Gut dysbiosis impacts the immune system and promotes prostate cancer.Immunology letters · 2024Review
- Development of Orally Ingestible IgA Antibody Drugs to Maintain Symbiosis Between Humans and Microorganisms.Advances in experimental medicine and biology · 2024Article
- Fecal Immunoglobulin Levels as a Modifier of the Gut Microbiome in Patients with Common Variable Immunodeficiency.Journal of clinical immunology · 2023Article
- Summary of the Joint National Institutes of Health and the Food and Drug Administration Workshop Titled "Exploring the Science Surrounding the Safe Use of Bioactive Ingredients in Infant Formula: Considerations for an Assessment Framework".The Journal of pediatrics · 2023Article
- Intestinal fungi and antifungal secretory immunoglobulin A in Crohn's disease.Frontiers in immunology · 2023Review
- Microbiome-Induced Autoimmunity and Novel Therapeutic Intervention.Advances in experimental medicine and biology · 2023Review
- Altered Immunoglobulin Repertoire and Decreased IgA Somatic Hypermutation in the Gut during Chronic HIV-1 Infection.Journal of virology · 2022Article
- Microbiome in Immune-Mediated Uveitis.International journal of molecular sciences · 2022Review
- Secreted immunoglobulin domain effector molecules of invertebrates and management of gut microbial ecology.Immunogenetics · 2022Review
- Deciphering the role of autophagy in the immunopathogenesis of inflammatory bowel disease.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggests that dysbiosis plays a role in the pathogenesis of intestinal diseases including inflammatory bowel disease (IBD) as well as extra-intestinal disorders. As a modulator of the intestinal microbiota, we isolated a mouse monoclonal IgA antibody (clone W27) with high affinities for multiple commensal bacteria, but not for beneficial bacteria such as Lactobacillus casei (L. casei). Via specific recognition of an epitope in serine hydroxymethyltransferase (SHMT), a bacterial metabolic enzyme, W27 IgA selectively inhibited the in vitro growth of bound bacteria, including Escherichia coli (E. coli), while having no effect on unbound beneficial bacteria such as L. casei. By modulating the gut microbiota in vivo, oral administration of W27 IgA effectively prevented development of colitis in several mouse models. Here we discuss how intestinal IgA modulates the gut microbiota through recognition of SHMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.